Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances
- 16 March 2020
- journal article
- research article
- Published by Springer Nature in Drugs
- Vol. 80 (6) , 525-534
Abstract
Erythrodermic psoriasis (EP) is an extreme and often refractory variant of psoriasis with high morbidity and increased mortality, and is frequently classified as a dermatological emergency. The pathophysiology of EP is largely unknown but is thought to differ from that of plaque psoriasis. Treatment of EP is challenging, and usually based on clinical experience and patient co-morbidities, due to its low incidence and limited clinical evidence. Conventional treatments, such as topical glucocorticoid therapy, cyclosporin, acitretin, and methotrexate have some but limited efficacy in EP, and treatment discontinuation may result in flares. Newer biological drugs, including anti-TNF, anti-IL-17, and anti-IL-12/23 agents, have shown promise in therapeutic management of EP, but most of the available evidence is currently based on small case series and reports. Few studies have compared available treatment options for EP, and further clinical studies are necessary to provide clinical data and optimal treatment guidelines for EP patients. Here, we provide a comprehensive review of the background of EP, assess the available clinical data on the efficacy of targeted therapies, and aim to provide a foundation for clinical decision making for this rare form of psoriasis.Keywords
This publication has 111 references indexed in Scilit:
- Ustekinumab Treatment of Erythrodermic Psoriasis Occurring after Physical Stress: A Report of Two CasesCase Reports in Dermatology, 2013
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trialThe Lancet, 2013
- Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trialThe Lancet, 2012
- Erythrodermic Psoriasis Improved by Panitumumab, But Not BevacizumabActa Dermato-Venereologica, 2012
- Fatal PML associated with efalizumab therapyNeurology, 2012
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe PsoriasisNew England Journal of Medicine, 2010
- Safety of Etanercept in PsoriasisDrug Safety, 2006
- Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesionsJournal of the American Academy of Dermatology, 2000
- Infectious complications of erythrodermic psoriasisJournal of the American Academy of Dermatology, 1996
- Detection of circulating adhesion molecules in erythrodermic skin diseaseJournal of the American Academy of Dermatology, 1995